Jaguar Health issues 54k shares to Streeterville in exchange for Series Q preferred; adjourns annual meeting to June 2

Jaguar Health, Inc.

Issued 54,222 common shares to Streeterville in exchange for 7.96 shares of Series Q Preferred Stock.
Common shares to be issued without restrictive legend; Streeterville can resell under Rule 144 using tacked holding period from Aug 2022.
Annual Meeting adjourned to June 2, 2026; supplement to proxy to be filed after discussions with Nasdaq staff.
Company plans to provide additional information to stockholders regarding certain proposals in the proxy statement.
Record date remains April 15, 2026 for the reconvened meeting.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Jaguar Health, Inc. entered into Exchange Agreements with Streeterville Capital, LLC valued at 54,222 shares of common stock in exchange for 7.96 shares of Series Q Preferred Stock (effective 2026-05-21).

Action: entry
Agreement: equity purchase
Counterparty: Streeterville Capital, LLC
Value: 54,222 shares of common stock in exchange for 7.96 shares of Series Q Preferred Stock
Effective: 2026-05-21

Exact text from the filing

On May 21, 2026, the Company entered into two privately negotiated exchange agreements with Streeterville (the “Exchange Agreements”), pursuant to which the Company issued an aggregate of 54,222 shares of the Company’s common stock, par value $0.0001 (the “Common Exchange Shares”) to Streeterville in exchange for an aggregate of 7.96 outstanding shares of Series Q Preferred Stock held by Streeterville (the “Exchanged Preferred Shares”).

View on SEC.gov

82 material agreements filed in the last 30 days. Browse all material agreements →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-237195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.